CPRX240719P20000
- 3.85
- 0.000.00%
Catalyst Pharmaceuticals Newsroom
Could The Market Be Wrong About Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Its Attractive Financial Prospects?
Catalyst Pharmaceuticals (NASDAQ:CPRX) has had a rough month with its share price down 8.7%. However, a closer look at its sound financials might cause you to think again. Given that fundamentals us
Catalyst Pharmaceuticals(CPRX.US) Officer Sells US$121.18K in Common Stock
$Catalyst Pharmaceuticals(CPRX.US)$ Officer Del Carmen Jeffrey sold 7,541 shares of common stock on Jun 7, 2024 at an average price of $16.07 for a total value of $121.18K.Source: Announcement What is
Form 144 | Catalyst Pharmaceuticals(CPRX.US) Officer Proposes to Sell 121.18K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 7, $Catalyst Pharmaceuticals(CPRX.US)$ Officer Del Carmen Jeffrey intends to sell 7,541 shares of its common stock on Jun 7, with a total market value of approximately $121
Catalyst Pharmaceuticals, Inc.'s (NASDAQ:CPRX) Stock Been Rising: Are Strong Financials Guiding The Market?
Catalyst Pharmaceuticals Price Target Maintained With a $29.00/Share by Oppenheimer
Catalyst Pharmaceuticals Price Target Maintained With a $29.00/Share by Oppenheimer
Express News | Reiterating its rating on Catalyst Pharmaceuticals (CPRX.US) from outperform to outperform and revising the target price from $29.00 to $29.00.
Oppenheimer Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Maintains Target Price $29
Oppenheimer analyst Leland Gershell maintains $Catalyst Pharmaceuticals(CPRX.US)$ with a buy rating, and maintains the target price at $29.According to TipRanks data, the analyst has a success rate of
Catalyst Pharmaceuticals(CPRX.US) Director Sells US$86,949.23 in Common Stock
$Catalyst Pharmaceuticals(CPRX.US)$ Director Harper Molly sold 5,333 shares of common stock on Jun 3, 2024 at an average price of $16.304 for a total value of $86,949.23.Source: Announcement What is s
Catalyst Pharmaceuticals Insider Sold Shares Worth $276,735, According to a Recent SEC Filing
Richard J Daly, Director, President and CEO, on June 04, 2024, sold 17,323 shares in Catalyst Pharmaceuticals (CPRX) for $276,735. Following the Form 4 filing with the SEC, Daly has control over a tot
Form 144 | Catalyst Pharmaceuticals(CPRX.US) Officer Proposes to Sell 1.29 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 5, $Catalyst Pharmaceuticals(CPRX.US)$ Officer INGENITO GARY intends to sell 80,000 shares of its common stock on Jun 5, with a total market value of approximately $1.29 mi
Form 144 | Catalyst Pharmaceuticals(CPRX.US) Officer Proposes to Sell 276.73K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 4, $Catalyst Pharmaceuticals(CPRX.US)$ Officer Daly Richard J intends to sell 17,323 shares of its common stock on Jun 4, with a total market value of approximately $276.73
H.C. Wainwright Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Maintains Target Price $26
H.C. Wainwright analyst Andrew Fein maintains $Catalyst Pharmaceuticals(CPRX.US)$ with a buy rating, and maintains the target price at $26.According to TipRanks data, the analyst has a success rate of
A Closer Look at 7 Analyst Recommendations For Catalyst Pharmaceuticals
Catalyst Pharmaceuticals (NASDAQ:CPRX) has been analyzed by 7 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.The following table summarizes their
HC Wainwright & Co. Reiterates Buy on Catalyst Pharmaceuticals, Maintains $26 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates Catalyst Pharmaceuticals (NASDAQ:CPRX) with a Buy and maintains $26 price target.
Express News | Catalyst Pharmaceuticals Shares up 2.1% After US FDA Approves Increased Maximum Daily Dose of Co's Neuromuscular Disorder Drug
Express News | Catalyst Pharmaceuticals:Raised Maximum Firdapse Daily Dose for Adults, Children Weighing Over 45 Kg From 80 Mg to 100 Mg for Treatmening Lems
Express News | Catalyst Pharmaceuticals Receives U.S. FDA Approval for Increased Maximum Daily Dose for Firdapse®
Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE
CORAL GABLES, Fla., May 30, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, de
Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024
CORAL GABLES, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, de
Institutional Investors in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Lost 6.2% Last Week but Have Reaped the Benefits of Longer-term Growth
Key Insights Given the large stake in the stock by institutions, Catalyst Pharmaceuticals' stock price might be vulnerable to their trading decisions The top 10 shareholders own 50% of the company